Weinmann Homecare Division has been acquired by a private investment group
A private investment group from Bad Ems, Germany has acquired the Homecare Division of Weinmann Geräte für Medizin GmbH + Co. KG (Weinmann Medical Technology). Financial details of the transaction have not been disclosed.
Weinmann Medical Technology develops and produces high quality diagnostic, therapeutic and lifesaving system solutions in its Homecare and Emergency business units. The Weinmann Emergency Division was re-established as an independent company prior to the sale of the limited partnership units. The separation of the two divisions allows a greater focus on the different markets.
The private investment group is one of the leading medical technology companies in Germany.
Oaklins' team in Germany exclusively advised the shareholders of Weinmann Geräte für Medizin GmbH + Co. KG in a global bidding process with interested parties from nearly every continent.
Talk to the deal team
Related deals
Instituto Sanitas and Chemopharma have been acquired by Laboratorios Saval
Instituto Sanitas and Chemopharma, leading pharmaceutical laboratories in Chile, have been acquired by Laboratorios Saval S.A., a prominent pharmaceutical company based in Chile with a regional presence across Latin America. The transaction strengthens Laboratorios Saval’s growth strategy and supports its expansion in the affordable medicines segment.
Learn moreRare Patient Voice has been acquired by Konovo
Rare Patient Voice has been acquired by Konovo, a technology-first healthcare intelligence company backed by Fraser Healthcare Partners.
Learn moreLindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn more